News

MSD to acquire Rigontec

Details

MSD today announced the acquisition of Rigontec for up to US$553M 

Themis: Chikungunya vaccine development towards Phase III trials receives £ 3 Mio. boost by Innovate UK

Details

The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate. 

Immatics initiates personalized adoptive cellular therapy in patients with relapsed and/or refractory solid cancers using its pioneering target warehouse

Details

Immatics today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse. 

  1. Themis starts Phase II clinical study of Chikungunya vaccine in endemic area
  2. 4SC secures EUR 41 million from successful capital increase
  3. Themis starts Phase II trial of Chikungunya vaccine in the U.S.
  4. Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO
© Wellington Partners, 2019.